Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Techne (TECH) EBIT (2016 - 2025)

Bio-Techne has reported EBIT over the past 17 years, most recently at $54.5 million for Q4 2025.

  • Quarterly results put EBIT at $54.5 million for Q4 2025, up 14.85% from a year ago — trailing twelve months through Dec 2025 was $117.0 million (down 41.58% YoY), and the annual figure for FY2025 was $102.3 million, down 50.53%.
  • EBIT for Q4 2025 was $54.5 million at Bio-Techne, up from $47.7 million in the prior quarter.
  • Over the last five years, EBIT for TECH hit a ceiling of $94.5 million in Q2 2023 and a floor of -$23.9 million in Q2 2025.
  • Median EBIT over the past 5 years was $59.3 million (2021), compared with a mean of $57.2 million.
  • Biggest five-year swings in EBIT: surged 74.46% in 2021 and later tumbled 152.07% in 2025.
  • Bio-Techne's EBIT stood at $62.3 million in 2021, then grew by 8.89% to $67.9 million in 2022, then crashed by 44.02% to $38.0 million in 2023, then increased by 24.77% to $47.4 million in 2024, then rose by 14.85% to $54.5 million in 2025.
  • The last three reported values for EBIT were $54.5 million (Q4 2025), $47.7 million (Q3 2025), and -$23.9 million (Q2 2025) per Business Quant data.